Compare Stocks: ENGN, OCGN, PBYI, and LRMR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$1.77 -4.3%	$1.79	$1.40 ▼ $12.25	$123.92M	-0.28	734,158 shs	368,436 shs
LRMR Larimar Therapeutics	$4.16 -2.1%	$3.80	$2.71 ▼ $6.42	$441.50M	0.81	1.22 million shs	1.16 million shs
OCGN Ocugen	$1.39 -6.1%	$1.35	$0.99 ▼ $2.73	$501.88M	2.21	4.34 million shs	3.95 million shs
PBYI Puma Biotechnology	$9.11 -4.0%	$8.15	$4.30 ▼ $9.51	$489.87M	1.22	300,197 shs	389,253 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	-4.32%	+4.73%	-8.29%	+7.93%	-54.15%
LRMR Larimar Therapeutics	-2.12%	-2.58%	+5.85%	+20.58%	+10.34%
OCGN Ocugen	-6.08%	+2.96%	+6.92%	+3.73%	+37.62%
PBYI Puma Biotechnology	-4.00%	+4.59%	+6.18%	+28.67%	+78.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENGN enGene	$1.77 -4.3%	$1.79	$1.40 ▼ $12.25	$123.92M	-0.28	734,158 shs	368,436 shs
LRMR Larimar Therapeutics	$4.16 -2.1%	$3.80	$2.71 ▼ $6.42	$441.50M	0.81	1.22 million shs	1.16 million shs
OCGN Ocugen	$1.39 -6.1%	$1.35	$0.99 ▼ $2.73	$501.88M	2.21	4.34 million shs	3.95 million shs
PBYI Puma Biotechnology	$9.11 -4.0%	$8.15	$4.30 ▼ $9.51	$489.87M	1.22	300,197 shs	389,253 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENGN enGene	-4.32%	+4.73%	-8.29%	+7.93%	-54.15%
LRMR Larimar Therapeutics	-2.12%	-2.58%	+5.85%	+20.58%	+10.34%
OCGN Ocugen	-6.08%	+2.96%	+6.92%	+3.73%	+37.62%
PBYI Puma Biotechnology	-4.00%	+4.59%	+6.18%	+28.67%	+78.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENGN enGene	2.14	Hold	$11.05	524.04% Upside
LRMR Larimar Therapeutics	3.10	Buy	$11.67	180.45% Upside
OCGN Ocugen	2.60	Moderate Buy	$9.50	583.45% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-34.14% Downside

Current Analyst Ratings Breakdown

Latest ENGN, OCGN, PBYI, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	ENGN enGene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/11/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/30/2026	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00
6/23/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/18/2026	ENGN enGene	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Equal Weight ➝ Underweight	$3.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENGN enGene	N/A	N/A	N/A	N/A	$2.60 per share	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$1.23 per share	N/A
OCGN Ocugen	$4.58M	102.90	N/A	N/A	($0.05) per share	-27.80
PBYI Puma Biotechnology	$228.40M	2.06	$0.80 per share	11.38	$2.68 per share	3.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENGN enGene	-$117.30M	-$2.17	N/A	N/A	N/A	N/A	-56.06%	-45.64%	9/14/2026 (Estimated)
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	11/4/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	17.52	50.61	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)

Latest ENGN, OCGN, PBYI, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/14/2026	Q3 2026	ENGN enGene	-$0.47	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A
6/15/2026	Q2 2026	ENGN enGene	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENGN enGene	$1.58	89.32%	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENGN enGene	0.10	12.57	12.57
LRMR Larimar Therapeutics	N/A	4.70	4.70
OCGN Ocugen	4.17	0.80	0.80
PBYI Puma Biotechnology	N/A	2.91	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENGN enGene	64.16%
LRMR Larimar Therapeutics	91.92%
OCGN Ocugen	10.27%
PBYI Puma Biotechnology	61.29%

Insider Ownership

Company	Insider Ownership
ENGN enGene	10.50%
LRMR Larimar Therapeutics	4.00%
OCGN Ocugen	3.95%
PBYI Puma Biotechnology	22.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENGN enGene	31	66.99 million	59.95 million	N/A
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
OCGN Ocugen	80	339.11 million	325.72 million	Optionable
PBYI Puma Biotechnology	200	51.62 million	40.16 million	Optionable

ENGN, OCGN, PBYI, and LRMR Headlines

Recent News About These Companies

Puma Biotechnology (NASDAQ:PBYI) Stock Rating Upgraded by Wall Street Zen

August 15, 2026 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen

August 15, 2026 | marketbeat.com

Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

August 12, 2026 | zacks.com

Puma Biotechnology (NASDAQ:PBYI) Price Target Raised to $6.00

August 10, 2026 | americanbankingnews.com

Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results, Beats Expectations By $0.15 EPS

August 7, 2026 | marketbeat.com

TD Cowen Forecasts Strong Price Appreciation for Puma Biotechnology (NASDAQ:PBYI) Stock

August 7, 2026 | marketbeat.com

PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

August 7, 2026 | zacks.com

Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Puma Biotechnology Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates

August 6, 2026 | zacks.com

Puma Biotechnology Reports Second Quarter 2026 Financial Results

August 6, 2026 | businesswire.com

Renaissance Technologies LLC Cuts Position in Puma Biotechnology, Inc. $PBYI

August 2, 2026 | marketbeat.com

Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline

July 30, 2026 | zacks.com

Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

July 23, 2026 | finance.yahoo.com

Douglas Hunt Sells 8,460 Shares of Puma Biotechnology (NASDAQ:PBYI) Stock

July 9, 2026 | insidertrades.com

Puma Biotechnology Shareholders Back Governance, Reject Warrant Extension

June 16, 2026 | tipranks.com

Puma Biotechnology (NASDAQ:PBYI) Director Brian Stuglik Sells 8,100 Shares

June 16, 2026 | insidertrades.com

Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why

June 11, 2026 | zacks.com

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2026 | businesswire.com

Puma Biotechnology Reveal Hidden Strength Amid Rising Market Focus

May 17, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENGN, OCGN, PBYI, and LRMR Company Descriptions

enGene NASDAQ:ENGN

$1.77 -0.08 (-4.32%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.03 (+1.75%)

As of 08:30 AM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Larimar Therapeutics NASDAQ:LRMR

$4.16 -0.09 (-2.12%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$4.25 +0.09 (+2.24%)

As of 08:30 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Ocugen NASDAQ:OCGN

$1.39 -0.09 (-6.08%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$1.40 +0.01 (+0.36%)

As of 08:29 AM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Puma Biotechnology NASDAQ:PBYI

$9.11 -0.38 (-4.00%)

Closing price 08/20/2026 04:00 PM Eastern

Extended Trading

$9.15 +0.04 (+0.48%)

As of 08:05 AM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENGN, OCGN, PBYI, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENGN, OCGN, PBYI, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENGN, OCGN, PBYI, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENGN, OCGN, PBYI, and LRMR Company Descriptions

enGene NASDAQ:ENGN

Larimar Therapeutics NASDAQ:LRMR

Ocugen NASDAQ:OCGN

Puma Biotechnology NASDAQ:PBYI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENGN, OCGN, PBYI, and LRMR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENGN, OCGN, PBYI, and LRMR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENGN, OCGN, PBYI, and LRMR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENGN, OCGN, PBYI, and LRMR Company Descriptions

enGene NASDAQ:ENGN

Larimar Therapeutics NASDAQ:LRMR

Ocugen NASDAQ:OCGN

Puma Biotechnology NASDAQ:PBYI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools